Systemic Therapy for Melanoma

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, Enjoy!

Issue link:

Contents of this Issue


Page 7 of 7

106 Commerce Street, Suite 105 Lake Mary, FL 32746 TEL: 407.878.7606 • FAX: 407.878.7611 Order additional copies at Copyright © 2020 All rights reserved Disclaimer is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y Guideline. is resource is a practice tool based on ASCO ® practice guidelines and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. is pocket guide does not purport to suggest any particular course of medical treatment. Use of the practice guidelines and this resource are voluntary. e practice guidelines and additional information are available at melanoma-guidelines. Copyright © 2020 by American Society of Clinical Oncolog y. All rights reserved. ASCOMEL03203 Abbreviations CLND, completion lymph node dissection; PD1, programmed death 1; SLNB, sentinel lymph node biopsy; US FDA, United States Food and Drug Administration Source Rahul Seth, Hans Messersmith, Varinder Kaur, John M. Kirkwood, Ragini Kudchadkar, Jennifer Leigh McQuade, Anthony Provenzano, Umang Swami, Jeffrey Weber, Krishna C. Alluri, Sanjiv Agarwala, Paolo A. Ascierto, Michael B. Atkins, Nancy Davis, Marc S. Ernstoff, Mark B. Faries, Jason S. Gold, Samantha Guild, David E. Gyorki, Nikhil I. Khushalani, Michael O. Meyers, Caroline Robert, Mario Santinami, Amikar Sehdev, Vernon K. Sondak, Gilliosa Spurrier, Katy K. Tsai, Alexander van Akkooi, Pauline Funchain. Systemic erapy for Melanoma: ASCO Guideline. J Clin Oncol. 2020 March 31doi: 10.1200/JCO.20.00198 ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care and that all patients should have the opportunity to participate. Additional information, which may include data supplements, slide sets, and other clinical tools and resources, is available at Recommendation Grading Type Benefit/harm Evidence Quality Strength of Recommendation EB Evidence-based B Benefits outweigh harms H High Strong FC Formal consensus H Harms outweigh benefits I Intermediate Moderate IC Informal consensus B/H Relative balance of benefits and harms L Low Weak N No recommendation U Unknown Ins Insufficient

Articles in this issue

Links on this page

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Systemic Therapy for Melanoma